Medical Developments International Valuation
Is MVP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MVP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MVP (A$0.42) is trading below our estimate of fair value (A$2.44)
Significantly Below Fair Value: MVP is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MVP?
Key metric: As MVP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is MVP's PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | AU$33.15m |
| Market Cap | AU$47.32m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | -3.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MVP's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.3x | ||
SPL Starpharma Holdings | 4.9x | n/a | AU$48.0m |
LGP Little Green Pharma | 1.5x | 16.3% | AU$39.2m |
NYR Nyrada | 6.5x | n/a | AU$21.0m |
VIT Vitura Health | 0.5x | n/a | AU$57.0m |
MVP Medical Developments International | 1.4x | 14.4% | AU$47.3m |
Price-To-Sales vs Peers: MVP is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (3.3x).
Price to Sales Ratio vs Industry
How does MVP's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?
| 17 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 4.9x | 35.5% | |
MVP Medical Developments International | 1.4x | 14.4% | US$30.75m |
MYX Mayne Pharma Group | 0.9x | 11.3% | US$236.25m |
PBP Probiotec | 1.1x | 6.7% | US$160.13m |
| 17 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 4.9x | 47.8% | |
MVP Medical Developments International | 1.4x | 93.1% | US$30.75m |
Price-To-Sales vs Industry: MVP is good value based on its Price-To-Sales Ratio (1.4x) compared to the Australian Pharmaceuticals industry average (4.9x).
Price to Sales Ratio vs Fair Ratio
What is MVP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | 2.3x |
Price-To-Sales vs Fair Ratio: MVP is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Neuren Pharmaceuticals
AU$1.6b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$12.36
7D
-26.0%
1Y
-17.0%
AVITA Medical
US$349.9m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.93
7D
2.3%
1Y
20.4%
Medical Developments International
AU$47.3m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.42
7D
-5.6%
1Y
-46.8%